EUVIMEDEUVIMED entdecken
Crossref

Leukotriene Inhibitors in the Prevention of Recurring Capsular Contracture in Secondary Breast Augmentation

Ignacio Oscar Procikieviez iD, Oscar Procikieviez

Aesthetic Plastic Surgery · 2024

DOI: 10.1007/s00266-024-04122-x ↗

Kurz gefasst

Fachartikel in der Zeitschrift Aesthetic Plastic Surgery, 2024. Verfasst von Ignacio Oscar Procikieviez und 1 weiteren Autor:innen. Beteiligte Einrichtung: Plastic and Reconstructive Surgery Service, 3076 Octavio Pinto Ave, 5009, Córdoba, Argentina. iproci8@hotmail.com. Hauptthemen laut MEDLINE: Leukotriene Antagonists, Implant Capsular Contracture, Acetates, Quinolines. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 13 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Capsular contracture (CC) remains a very common complication and the main cause of reoperation following a mammary implant surgery. Leukotrienes play an important role in the inflammatory cascade linked to the development of the periprosthetic capsule. The aim of this paper is to evaluate the incidence of recurrence of capsular contracture in female patients who underwent a secondary mammary augmentation due to this etiology, with and without treatment with leukotriene inhibitors during postoperative care. MATERIAL AND METHODS: Sixty-four women submitted to a secondary mammary augmentation due to CC were evaluated retrospectively. Out of these patients, 20 (31%) were treated with Montelukast for 3 months. The remaining 44 (69%) did not receive antileukotriene. The presence of capsular contracture was measured using the Baker classification and magnetic resonance imaging a year after postoperative care. The median follow-up period was 15 months. RESULTS: The patients receiving Montelukast (n = 20) presented a 15% CC rate (n = 1). The women that did not receive antileukotriene therapy (n = 44) presented a 16% CC rate (n = 7). CONCLUSION: The results of our study show that treatment with Montelukast for 3 months after the operation is associated with lower rates of capsular contracture when compared to patients that did not receive the treatment. LEVEL OF EVIDENCE III: This journal requires that authors assign a level of evidence to each article. For a full description of these Evidence-Based Medicine ratings, please refer to the Table of Contents or the online Instructions to Authors www.springer.com/00266 .

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Leukotriene AntagonistsImplant Capsular ContractureAcetatesQuinolinesBreast ImplantsBreast ImplantationMammaplastyHumansFemaleRetrospective StudiesCyclopropanesAdultSulfidesMiddle AgedTreatment OutcomeReoperationFollow-Up StudiesCohort StudiesRecurrenceRisk AssessmentSecondary PreventionYoung Adult

Stichwörter der Autor:innen

Capsular contractureLeukotrienesMammary implantMastoplastyMontelukast

Substanzen

Leukotriene AntagonistsCyclopropanesmontelukastSulfidesAcetatesQuinolines

Autor:innen und Institutionen

  • Plastic and Reconstructive Surgery Service, 3076 Octavio Pinto Ave, 5009, Córdoba, Argentina. iproci8@hotmail.com.
  • Chief of Plastic and Reconstructive Surgery Service, Córdoba, Argentina.

ORCID-Profile: Ignacio Oscar Procikieviez

Zitieren

APA

Procikieviez, I. O., & Procikieviez, O. (2024). Leukotriene Inhibitors in the Prevention of Recurring Capsular Contracture in Secondary Breast Augmentation. Aesthetic Plastic Surgery. https://doi.org/10.1007/s00266-024-04122-x

Vancouver

Procikieviez IO, Procikieviez O. Leukotriene Inhibitors in the Prevention of Recurring Capsular Contracture in Secondary Breast Augmentation. Aesthetic Plastic Surgery. 2024. doi:10.1007/s00266-024-04122-x

BibTeX
@article{Procikieviez2024,
  author = {Procikieviez, Ignacio Oscar and Procikieviez, Oscar},
  title = {Leukotriene Inhibitors in the Prevention of Recurring Capsular Contracture in Secondary Breast Augmentation},
  journal = {Aesthetic Plastic Surgery},
  year = {2024},
  doi = {10.1007/s00266-024-04122-x}
}
Kostenlos starten →